Physician profile
Randal Brown
NPI 1831167956
$9,701.45
in general payments reported to CMS, 2019-2025
44 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $1,316 · 2021: $1,832 · 2022: $1,350 · 2023: $1,533 · 2024: $1,420 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,035 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,034.66 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,387.20 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $907.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $877.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $808.48 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $539.81 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $438.37 | 2020-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.24 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $405.05 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $381.41 | 2019-2025 | Xarelto, Spravato |
| Amgen INC. | $342.48 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $316.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $269.61 | 2021-2025 | |
| Eisai INC. | $269.50 | 2020-2022 | |
| Dexcom, INC. | $250.62 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $234.68 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randal Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.